Search

Objective: To discuss the safety of secukinumab treatment during pregnancy, and to provide the reference for the treatment of psoriasis patients during pregnancy. Methods：A case of pustular psoriasis safely treated with secukinumab during pregnancy was collected and combined with the relevant literature review, the safety of secukinumab treatment for the psoriasis during pregnancy was analyzed. Results: The patient was a 28-year-old woman with a body weight of 50 kg. The patient had been experiencing generalized erythema and scales for 5 years, which worsened with pustules for 1 year. The dermatology examination results showed large patches of erythema, silver-white scales and small pustules on the skin of the patient, no changes in the nails, and was not accompanied by the joint symptoms. The patient was diagnosed as generalized pustular psoriasis. After being treated with secukinumab for 2 months, the psoriasis area and severity index （PASI） was 0； the patient unexpectedly became pregnant after treated for 10 months. Secukinumab was continued throughout the pregnancy until 20 d before delivery, and the patient gave birth to a healthy full-term female baby with the body weight of 3. 6 kg. Conclusion：Secukinumab can be used as a therapeutic option for the patients with psoriasis during pregnancy, but more clinical cases and drug research are needed to evaluate its safety during pregnancy [ABSTRACT FROM AUTHOR]

Objective To observe the efficacy of dupilumab in the treatment of refractory atopic dermatitis (AD)，and to provide the reference for the treatment of such patients. Methods The clinical data and follow-up results of two patients with refractory severe AD treated with dupilumab were collected; combined with the literature review, the efficacy and safety of dupilumab in the treatment of refractory AD were analyzed. Results Patient 1 was a 30-year-old female with dense, infiltrated papules on the back of both hands, resembling lichenified skin changes, scattered erythema, and papules with itching on the limbs and trunk for 25 years. Patient 1 also had a history of allergic rhinitis for 5 years. The diagnosis was adults severe AD. After 16 weeks of treatment with dupilumab, the skin lesions were completely regressed, and there were no relapse during the follow-up period. The symptoms of allergic rhinitis was improved significantly, and oral medication was no longer needed. Patient 2 was a 59-year-old female with general dark red erythema, papules, and nodules accompanied by itching for over 10 years. Patient 2 had been hospitalized many times and had previously received treatment with cyclosporine, azathioprine, and steroids with unsatisfactory results. The diagnosis was adults severe AD. Up to the present, the skin lesions had essentially regressed after treatment with dupilumab. Conclusion Dupilumab has good curative effect and safety on refractory AD, and it can improve the life quality, and controll the charicteristics of AD complicated with other allergic diseases driven by type 2 inflammation. [ABSTRACT FROM AUTHOR]